We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
-15.88%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$104M
AUM Growth
–
Cap. Flow
+$113M
Cap. Flow %
108.47%
Top 10 Hldgs %
95.41%
Holding
17
New
17
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$24.3M
2
ALLK
Allakos
ALLK
+$23M
3
STRO icon
Sutro Biopharma
STRO
+$13.6M
4
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$9.88M
5
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$9.28M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 99.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALLK
1
DELISTED
Allakos
ALLK
$24M 23%
+458,366
New +$23M
ICPT
2
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$23.6M 22.67%
+234,375
New +$24.3M
PRNB
3
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$10.5M 10.08%
+383,480
New +$9.88M
STRO icon
4
Sutro Biopharma
STRO
$379M
$10.2M 9.75%
+112,558
New +$13.6M
ODT
5
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$8.39M 8.05%
+595,850
New +$9.28M
LQDA icon
6
Liquidia Corp
LQDA
$7.67B
$8.2M 7.87%
+378,420
New +$8.85M
SYRS
7
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$5.9M 5.67%
+105,994
New +$8.05M
KALV
8
DELISTED
KalVista Pharmaceuticals
KALV
$2.96M 2.84%
+150,000
New +$3.02M
EVLO
9
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$2.96M 2.84%
+11,376
New +$2.29M
VRDN icon
10
Viridian Therapeutics
VRDN
$2.13B
$2.75M 2.64%
+60,606
New +$3.51M
ARAV
11
DELISTED
Aravive, Inc. Common Stock
ARAV
$1.56M 1.5%
+442,733
New +$2.55M
ATXS
12
DELISTED
Astria Therapeutics
ATXS
$1.31M 1.26%
+50,000
New +$1.89M
UROV
13
DELISTED
Urovant Sciences Ltd.
UROV
$1.04M 1%
+157,480
New +$1.43M
TPST icon
14
Tempest Therapeutics
TPST
$14.8M
$359K 0.34%
+231
New +$475K
SURF
15
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$332K 0.32%
+78,300
New +$605K
TRIL
16
DELISTED
Trillium Therapeutics Inc.
TRIL
$122K 0.12%
+71,619
New +$215K
PDSB icon
17
PDS Biotechnology
PDSB
$38.1M
$59K 0.06%
+9,167
New +$121K

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
GSIS
Global Strategic Investment Solutions Scottsdale, Arizona $1.03B AUM 16.75% 1-Year Est. Return
RIM
RW Investment Management Eagle, Idaho $1.03B AUM
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return

Samsara BioCapital's Q4 2018 Portfolio in Review

Q4 2018 is the first quarter with a 13F filing on record for Samsara BioCapital, which disclosed 17 positions worth $104M. Its ten largest holdings account for 95% of the portfolio.

Its largest position is Intercept Pharmaceuticals, Inc.: 234,375 shares worth $23.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • Samsara BioCapital's largest Q4 2018 buy was Intercept Pharmaceuticals, Inc.: 234,375 shares worth $23.6M.
  • Samsara BioCapital's ten largest holdings make up 95% of its $104M portfolio in Q4 2018.
  • Samsara BioCapital disclosed 17 positions in Q4 2018, its first 13F filing on record.

Based on Samsara BioCapital's 13F filing for Q4 2018, filed 14 Feb 2019.